SETTING:Isoniazid preventive therapy (IPT) has not been widely implemented due to questions about acceptance, adherence and side effects. OBJECTIVE: To examine factors related to completion of IPT among human immunodeficiency virus (HIV) infected subjects in Tanzania. DESIGN: HIV-infected subjects in the DarDar TB vaccine trial with CD4 cell counts >or=200 cells/mm(3) and a positive tuberculin skin test (TST) were counseled, offered IPT for 6 months and seen monthly. RESULTS: Among 1932 subjects, TST results were positive in 631 (33%): 568 (90%) were offered IPT, 565 (99%) accepted and three (<1%) refused. Of the 565 subjects who accepted IPT, 493 (87%) completed treatment and 72 (13%) did not. Non-completion was physician-initiated in 24 (33%, due to active TB or side effects), patient-initiated in 42 (58%, due to self-cessation or loss to follow-up) and due to death in 6 (8%, unrelated to IPT). Interviews were conducted among 109 completers and 20 non-completers (12 physician- and 8 patient-initiated). Completers were motivated by fear of TB (44%), understanding the importance of IPT (32%) and counseling (22%). Patient-initiated non-completers were dissuaded by stigma (58%), side effects (14%) and travel distance (1%). CONCLUSIONS: HIV-infected subjects provided with counseling, monthly follow-up and travel reimbursement have high rates of IPT completion with minimal side effects.
RCT Entities:
SETTING:Isoniazid preventive therapy (IPT) has not been widely implemented due to questions about acceptance, adherence and side effects. OBJECTIVE: To examine factors related to completion of IPT among human immunodeficiency virus (HIV) infected subjects in Tanzania. DESIGN:HIV-infected subjects in the DarDar TB vaccine trial with CD4 cell counts >or=200 cells/mm(3) and a positive tuberculin skin test (TST) were counseled, offered IPT for 6 months and seen monthly. RESULTS: Among 1932 subjects, TST results were positive in 631 (33%): 568 (90%) were offered IPT, 565 (99%) accepted and three (<1%) refused. Of the 565 subjects who accepted IPT, 493 (87%) completed treatment and 72 (13%) did not. Non-completion was physician-initiated in 24 (33%, due to active TB or side effects), patient-initiated in 42 (58%, due to self-cessation or loss to follow-up) and due to death in 6 (8%, unrelated to IPT). Interviews were conducted among 109 completers and 20 non-completers (12 physician- and 8 patient-initiated). Completers were motivated by fear of TB (44%), understanding the importance of IPT (32%) and counseling (22%). Patient-initiated non-completers were dissuaded by stigma (58%), side effects (14%) and travel distance (1%). CONCLUSIONS:HIV-infected subjects provided with counseling, monthly follow-up and travel reimbursement have high rates of IPT completion with minimal side effects.
Authors: Lisa V Adams; Barry N Kreiswirth; Robert D Arbeit; Hanna Soini; Lillian Mtei; Mecky Matee; Muhammad Bakari; Timothy Lahey; Wendy Wieland-Alter; Elena Shashkina; Natalia Kurepina; Jeffrey R Driscoll; Kisali Pallangyo; C Robert Horsburgh; C Fordham von Reyn Journal: J Clin Microbiol Date: 2012-05-30 Impact factor: 5.948
Authors: J L Kadota; A Katamba; A Musinguzi; F Welishe; J Nabunje; J L Ssemata; C A Berger; M R Kamya; J Namusobya; F C Semitala; A Cattamanchi; D W Dowdy Journal: Int J Tuberc Lung Dis Date: 2020-07-01 Impact factor: 2.373
Authors: Mark J Siedner; Alexander Lankowski; Alexander C Tsai; Conrad Muzoora; Jeffrey N Martin; Peter W Hunt; Jessica E Haberer; David R Bangsberg Journal: AIDS Date: 2013-06-01 Impact factor: 4.177
Authors: Neil A Martinson; Grace L Barnes; Lawrence H Moulton; Reginah Msandiwa; Harry Hausler; Malathi Ram; James A McIntyre; Glenda E Gray; Richard E Chaisson Journal: N Engl J Med Date: 2011-07-07 Impact factor: 91.245
Authors: Khai Hoan Tram; Florence Mwangwa; Gabriel Chamie; Mucunguzi Atukunda; Asiphas Owaraganise; James Ayieko; Vivek Jain; Tamara D Clark; Dalsone Kwarisiima; Maya L Petersen; Moses R Kamya; Edwin D Charlebois; Diane V Havlir; Carina Marquez Journal: AIDS Care Date: 2019-06-10
Authors: Timothy Lahey; Todd Mackenzie; Robert D Arbeit; Muhammad Bakari; Lillian Mtei; Mecky Matee; Isaac Maro; C Robert Horsburgh; Kisali Pallangyo; C Fordham von Reyn Journal: Clin Infect Dis Date: 2012-09-12 Impact factor: 9.079